Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Infra-tentorial gliomas
Inherited predisposition to cancer
Multicentric gliomas
Non-canonical IDH mutant gliomas
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
21
09
2020
accepted:
09
11
2020
pubmed:
19
11
2020
medline:
21
10
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
Approximately 10% of IDH-mutant gliomas harbour non-canonical IDH mutations (non-p.R132H IDH1 and IDH2 mutations). The aim of this study was to analyse the characteristics of non-canonical IDH-mutant gliomas. We retrospectively analysed the characteristics of 166 patients with non-canonical IDH mutant gliomas and compared them to those of 155 consecutive patients with IDH1 p.R132H mutant gliomas. The median age at diagnosis was 38 years in patients with non-canonical IDH mutant gliomas and 43 years in glioma patients with IDH1 p.R132H-mutant tumours. Family history of cancer was more frequent among glioma patients harbouring non-canonical IDH mutations than in patients with IDH1 p.R132H mutations (22.2% vs 5.1%; P < 0.05). Tumours were predominantly localised in the frontal lobe regardless of the type of IDH mutation. Compared to IDH1 p.R132H-mutant gliomas, tumours with non-canonical IDH mutations were more frequently found in the infratentorial region (5.5% vs 0%; P < 0.05) and were often multicentric (4.8% vs 0.9%; P < 0.05). Compared to IDH1 P.R132H-mutant gliomas, tumours with non-canonical IDH1 mutations were more frequently astrocytomas (65.6% vs 43%, P < 0.05), while those with IDH2 mutations were more frequently oligodendrogliomas (85% vs 48.3%; P < 0.05). The median overall survival was similar in patients with IDH1 p.R132H-mutant gliomas and patients with non-canonical IDH-mutant gliomas. Gliomas with non-canonical IDH mutations have distinct radiological and histological characteristics. The presence of such tumours seems to be associated with genetic predisposition to cancer development.
Sections du résumé
BACKGROUND
BACKGROUND
Approximately 10% of IDH-mutant gliomas harbour non-canonical IDH mutations (non-p.R132H IDH1 and IDH2 mutations).
OBJECTIVE
OBJECTIVE
The aim of this study was to analyse the characteristics of non-canonical IDH-mutant gliomas.
MATERIALS AND METHODS
METHODS
We retrospectively analysed the characteristics of 166 patients with non-canonical IDH mutant gliomas and compared them to those of 155 consecutive patients with IDH1 p.R132H mutant gliomas.
RESULTS
RESULTS
The median age at diagnosis was 38 years in patients with non-canonical IDH mutant gliomas and 43 years in glioma patients with IDH1 p.R132H-mutant tumours. Family history of cancer was more frequent among glioma patients harbouring non-canonical IDH mutations than in patients with IDH1 p.R132H mutations (22.2% vs 5.1%; P < 0.05). Tumours were predominantly localised in the frontal lobe regardless of the type of IDH mutation. Compared to IDH1 p.R132H-mutant gliomas, tumours with non-canonical IDH mutations were more frequently found in the infratentorial region (5.5% vs 0%; P < 0.05) and were often multicentric (4.8% vs 0.9%; P < 0.05). Compared to IDH1 P.R132H-mutant gliomas, tumours with non-canonical IDH1 mutations were more frequently astrocytomas (65.6% vs 43%, P < 0.05), while those with IDH2 mutations were more frequently oligodendrogliomas (85% vs 48.3%; P < 0.05). The median overall survival was similar in patients with IDH1 p.R132H-mutant gliomas and patients with non-canonical IDH-mutant gliomas.
CONCLUSION
CONCLUSIONS
Gliomas with non-canonical IDH mutations have distinct radiological and histological characteristics. The presence of such tumours seems to be associated with genetic predisposition to cancer development.
Identifiants
pubmed: 33205355
doi: 10.1007/s11060-020-03662-x
pii: 10.1007/s11060-020-03662-x
doi:
Substances chimiques
IDH2 protein, human
EC 1.1.1.41
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-286Investigateurs
C Desenclos
(C)
H Sevestre
(H)
P Menei
(P)
A Rousseau
(A)
T Cruel
(T)
S Lopez
(S)
M-I Mihai
(MI)
A Petit
(A)
C Adam
(C)
F Parker
(F)
R Seizeur
(R)
I Quintin-Roué
(I)
S Eimer
(S)
H Loiseau
(H)
L Bekaert
(L)
F Chapon
(F)
D Ricard
(D)
C Godfraind
(C)
T Khallil
(T)
D Cazals-Hatem
(D)
T Faillot
(T)
C Gaultier
(C)
M C Tortel
(MC)
I Carpiuc
(I)
P Richard
(P)
W Lahiani
(W)
H Aubriot-Lorton
(H)
F Ghiringhelli
(F)
E Le Rhun
(E)
C A Maurage
(CA)
E M Gueye
(EM)
F Labrousse
(F)
F Ducray
(F)
D Meyronnet
(D)
D Figarella-Branger
(D)
O Chinot
(O)
L Bauchet
(L)
V Rigau
(V)
P Beauchesne
(P)
G Gauchotte
(G)
M Campone
(M)
D Loussouarn
(D)
D Fontaine
(D)
F Vandenbos-Burel
(F)
C Blechet
(C)
M Fesneau
(M)
A Carpentier
(A)
C Dehais
(C)
J Y Delattre
(JY)
K Mokhtari
(K)
M Polivka
(M)
S Milin
(S)
M Wager
(M)
P Colin
(P)
M D Diebold
(MD)
D Chiforeanu
(D)
E Vauleon
(E)
O Langlois
(O)
A Laquerriere
(A)
F Forest
(F)
M J Motso-Fotso
(MJ)
M Andraud
(M)
G Runavot
(G)
B Lhermitte
(B)
G Noel
(G)
A L Di Stéfano
(AL)
C Villa
(C)
C Rousselot-Denis
(C)
I Zemmoura
(I)
N Desse
(N)
E Cohen-Moyal
(E)
E Uro-Coste
(E)
F Dhermain
(F)
Références
Yan H, McLendon R, Kos I, Riggins GJ, Reardon D, Velculescu VE et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
doi: 10.1056/NEJMoa0808710
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820
doi: 10.1007/s00401-016-1545-1
Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H (2009) Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117(6):653–656
doi: 10.1007/s00401-009-0528-x
Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Ducray F (2016) Characteristics of gliomas in patients with somatic IDH mosaicism. Acta Neuropathol Commun 4(1):1–8
doi: 10.1186/s40478-016-0302-y
Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M et al (2018) FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 90(23):e2086–e2094
doi: 10.1212/WNL.0000000000005658
Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD et al (2018) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology 20(5):632–641
doi: 10.1093/neuonc/nox205
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Figarella-Branger D (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132(4):625–634
doi: 10.1007/s00401-016-1611-8
Weller M, Van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Wick W (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18(6):e315–e329
doi: 10.1016/S1470-2045(17)30194-8
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508
doi: 10.1056/NEJMoa1407279
Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I et al (2018) Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathol 135(5):743–755
doi: 10.1007/s00401-018-1825-z
Kyritsis AP, Bondy ML, Rao JS, Sioka C (2010) Inherited predisposition to glioma. Neuro-Oncology 12:104–113
doi: 10.1093/neuonc/nop011
Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM et al (2012) A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 44(10):1122–1125
doi: 10.1038/ng.2388
Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E et al (2017) Characteristics of H3 K27M-mutant gliomas in adults. Neuro-Oncology 19(8):1127–1134
doi: 10.1093/neuonc/now274
Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D (2017) Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol 134(3):541–549
doi: 10.1007/s11060-017-2393-0
Lu VM, McDonald KL (2018) Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma. CNS Oncol 7(1):41–50
doi: 10.2217/cns-2017-0019
Akimoto J, Sasaki H, Haraoka R, Nakajima N, Fukami S, Kohno M (2014) A case of radiologically multicentric but genetically identical multiple glioblastomas. Brain Tumor Pathol 31(2):113–117
doi: 10.1007/s10014-013-0157-x
Lombardi G, Della Puppa A, Gardiman MP, Rossi S, Candiotto C, Zanatta L et al (2018) Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma. Neuro-Oncology 20(8):1142–1143
doi: 10.1093/neuonc/noy080
Galuppini F, Opocher E, Tabori U, Mammi I, Edwards M, Campbell B et al (2018) Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. Neuropathol Appl Neurobiol 44(2):233–239
doi: 10.1111/nan.12450
Auré K, Laigle-Donadey F, Kaloshi G, Amiel-Benouaich A, Sanson M (2006) Les gliomes multiples: étude clinique et hypothèses physiopathologiques. Rev Neurol 162(8–9):845–851
doi: 10.1016/S0035-3787(06)75088-3
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474
doi: 10.1007/s00401-009-0561-9
Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Uro-Coste E (2018) IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro-Oncology 20(5):716–718
pubmed: 29522183
pmcid: 5892154